Mount Sinai seeks EUA from Food and Drug Administration for potential quantitative serologic test for COVID-19

If authorized for quantitative use, the assay could be used to provide a numeric result for the concentration of neutralizing anti-COVID-19 antibodies in plasma.

Mount Sinai Health System and Renalytix Form Joint Venture, Kantaro Biosciences, To Develop and Scale Production of COVID Antibody Test Kits

– Kantaro Biosciences partners with Bio-Techne for manufacturing and global kit distribution
– Scaled kit production to enable clinical laboratories to conduct 10M tests per month is planned to begin in July

Mount Sinai and Harbour BioMed Collaborate to Advance Novel Biotherapies for the Treatment of Cancer and Coronavirus COVID-19

Collaboration combines Harbour BioMed’s proprietary H2L2 Harbour Mice® platform for fully human monoclonal antibody generation with Mount Sinai’s translational medical research expertise.